Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02665208 · ClinicalTrials.gov registry record · NA

A Pilot Text Messaging Intervention to Reduce Smoking in Office-based Buprenorphine and Inpatient Detoxification Patients

A NA study, sponsored by NYU Langone Health.

Completed
Registry status
NA
Development phase
203
Enrollment target

NCT02665208 is a NA study that has completed, run by NYU Langone Health. The registered enrollment target is 203 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02665208, a NA study, has completed, sponsored by NYU Langone Health.

COMPLETED
Registry status
NA
Development phase
203 participants
Enrollment target

Study Summary

The primary purpose of this study is to understand the feasibility of a text messaging intervention developed by the National Cancer Institute, known as Smokefreetxt, to improve smoking cessation among opiate and/or alcohol dependent participants discharged from an inpatient detoxification unit and enrolled in an office-based buprenorphine program patients (OBBP). Participants will be randomized to 1) treatment as usual (TAU) comprised of informational pamphlets and information for a 1800 quit line; and a prescription for a nicotine replacement therapy (NRT) (i.e. nicotine replacement patches based on the quantity of baseline self-reported smoking, or nicotine replacement gum (2mg) #10, for 28 days which is offered routinely to all inpatients at Bellevue at the time of discharge) versus the SmokeFreeTXT intervention plus prescriptions for NRT.

Interventions

  • DRUG Nicotine Replacement Therapies
  • OTHER Treatment As Usual (TAU)
  • BEHAVIORAL Text Message Intervention (TMI)

Trial Details

FieldValue
Enrollment Target 203 participants
Start Date 2015-03
Est. Completion 2017-09
Phase NA

Sponsor

NYU Langone Health

1,164 total trials

What the Registry Record Tells You About NCT02665208

The ClinicalTrials.gov registry entry for NCT02665208 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 203 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Nicotine Replacement Therapies is the first listed.

NCT02665208 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02665208 about?

NCT02665208 is a clinical study titled "A Pilot Text Messaging Intervention to Reduce Smoking in Office-based Buprenorphine and Inpatient Detoxification Patients". The primary purpose of this study is to understand the feasibility of a text messaging intervention developed by the National Cancer Institute, known as Smokefreetxt, to improve smoking cessation among opiate and/or alcohol dependent participants discharged from an inpatient detoxification unit and ...

What is the current status of trial NCT02665208?

This trial is currently completed. It is a NA study. The enrollment target is 203 participants. The study started on 2015-03. Estimated completion is 2017-09.

What interventions are being tested in trial NCT02665208?

The interventions under investigation include: Nicotine Replacement Therapies (DRUG), Treatment As Usual (TAU) (OTHER), Text Message Intervention (TMI) (BEHAVIORAL).

Who is sponsoring clinical trial NCT02665208?

This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.